MA31949B1 - Dérivés d'aminotriazole comme agonistes d'alx - Google Patents

Dérivés d'aminotriazole comme agonistes d'alx

Info

Publication number
MA31949B1
MA31949B1 MA32968A MA32968A MA31949B1 MA 31949 B1 MA31949 B1 MA 31949B1 MA 32968 A MA32968 A MA 32968A MA 32968 A MA32968 A MA 32968A MA 31949 B1 MA31949 B1 MA 31949B1
Authority
MA
Morocco
Prior art keywords
alx
antagonist
aminotriazole derivatives
derivatives act
aminotriazole
Prior art date
Application number
MA32968A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel Bur
Sylvaine Cren
Olivier Corminboeuf
Corinna Grisostomi
Xavier Leroy
Sylvia Richard-Bildstein
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA31949B1 publication Critical patent/MA31949B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La présente invention concerne des dérivés d'aminotriazole de la formule (i), dans laquelle a, e, r1 et r2 sont tels que définis dans la description, ainsi que leur préparation et leur utilisation comme composés pharmaceutiquement actifs. Les composés sont utiles pour la prévention ou le traitement de maladies qui répondent à la modulation du récepteur alx telles que des maladies inflammatoires.
MA32968A 2007-12-18 2010-06-29 Dérivés d'aminotriazole comme agonistes d'alx MA31949B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2007055199 2007-12-18
IB2008054369 2008-10-23
PCT/IB2008/055375 WO2009077990A1 (fr) 2007-12-18 2008-12-17 Dérivés d'aminotriazole comme agonistes d'alx

Publications (1)

Publication Number Publication Date
MA31949B1 true MA31949B1 (fr) 2010-12-01

Family

ID=40404773

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32968A MA31949B1 (fr) 2007-12-18 2010-06-29 Dérivés d'aminotriazole comme agonistes d'alx

Country Status (26)

Country Link
US (1) US8536209B2 (fr)
EP (1) EP2225231B1 (fr)
JP (1) JP4656674B2 (fr)
KR (1) KR101213007B1 (fr)
CN (1) CN101903378B (fr)
AR (1) AR069801A1 (fr)
AT (1) ATE520689T1 (fr)
AU (1) AU2008337097B2 (fr)
BR (1) BRPI0821115A8 (fr)
CA (1) CA2706839C (fr)
CY (1) CY1112465T1 (fr)
DK (1) DK2225231T3 (fr)
HK (1) HK1144158A1 (fr)
HR (1) HRP20110825T1 (fr)
IL (1) IL206399A (fr)
MA (1) MA31949B1 (fr)
MX (1) MX2010006241A (fr)
MY (1) MY153985A (fr)
NZ (1) NZ586735A (fr)
PL (1) PL2225231T3 (fr)
PT (1) PT2225231E (fr)
RU (1) RU2492167C2 (fr)
SI (1) SI2225231T1 (fr)
TW (1) TWI434685B (fr)
WO (1) WO2009077990A1 (fr)
ZA (1) ZA201005080B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
DK2432760T3 (da) * 2009-05-18 2013-09-08 Actelion Pharmaceuticals Ltd Brokoblede spiro [2.4]-heptanderivater som alx-receptor og/eller fprl2-agonister
US8580831B2 (en) 2009-06-09 2013-11-12 Actelion Pharmaceuticals Ltd. Fluorinated aminotriazole derivatives
CA2760887A1 (fr) * 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Derives de l'oxazole et du thiazole en tant qu'agonistes du recepteur alx
CA2814826C (fr) 2010-11-17 2019-02-12 Actelion Pharmaceuticals Ltd Derives a ponts ester de spiro [2.4] heptane
AR084172A1 (es) * 2010-12-07 2013-04-24 Actelion Pharmaceuticals Ltd Derivados aminotriazol hidroxilados como agonistas del receptor alx
PL2649068T3 (pl) * 2010-12-07 2015-03-31 Idorsia Pharmaceuticals Ltd Pochodne eteru oksazolilowo-metylowego jako agoniści receptora ALX
US20140113824A1 (en) 2011-05-10 2014-04-24 Bayer Intellectual Property Gmbh Bicyclic (thio)carbonylamidines
WO2013022766A1 (fr) * 2011-08-05 2013-02-14 Flynn Gary A Préparation et procédés d'utilisation d'ortho-aryle hétéroaryle à 5 chaînons -carboxamide contenant des inhibiteurs de kinases multicibles
CN102558117B (zh) * 2011-12-15 2014-10-08 北京金骄生物质化工有限公司 一种利用废弃生物质制备5-硝基-2-糠酸酯的方法
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
WO2013171687A1 (fr) 2012-05-16 2013-11-21 Actelion Pharmaceuticals Ltd Dérivés pontés substitués par 1-(p-tolyl)cyclopropyle de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
AU2013328301A1 (en) 2012-10-10 2015-05-28 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives
CN104968657A (zh) * 2012-12-03 2015-10-07 弗·哈夫曼-拉罗切有限公司 被取代的***和咪唑化合物
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
AR096686A1 (es) 2013-06-25 2016-01-27 Actelion Pharmaceuticals Ltd Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx
JP6330038B2 (ja) 2013-07-18 2018-05-23 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ａｌｘ受容体アゴニストとしてのピペラジン置換架橋スピロ［２．４］ヘプタン誘導体
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
CN105814019B (zh) 2013-11-28 2019-12-06 杏林制药株式会社 脲衍生物、或其药理学上所容许的盐
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
JP6746614B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
ES2814126T3 (es) 2015-05-27 2021-03-26 Kyorin Seiyaku Kk Derivado de urea o sal farmacológicamente aceptable del mismo
EP3380091A1 (fr) * 2015-11-24 2018-10-03 Bristol-Myers Squibb Company Ciblage du récepteur 2 de peptide formyle / du récepteur de la lipoxine a4 (fpr2/alx) pour le traitement de maladies cardiaques
WO2019173182A1 (fr) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Agonistes du récepteur 2 du peptide formylé de phénylpyrrolidinone
US11629143B2 (en) 2020-10-01 2023-04-18 Vibliome Therapeutics, Llc HipK4 inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62234018A (ja) 1986-04-02 1987-10-14 Rooto Seiyaku Kk 糖尿病併発症治療剤
WO2003035006A2 (fr) 2001-10-26 2003-05-01 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Amyloide $g(b), ligand des recepteurs de la classe fpr
US20050164305A1 (en) 2002-04-03 2005-07-28 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
BRPI0416272A (pt) 2003-11-07 2007-01-09 Acadia Pharm Inc usos do receptor fprl1, e de compostos, uso profilático de compostos, métodos de triagem para um composto capaz de afetar uma ou mais atividades de um receptor fprl1, de tratamento ou prevenção de inflamação, de identificação de um composto de indução de vasodilatação, para antagonismo de uma resposta vasoconstrutiva a um sulfidopeptìdeo leucotrieno em um indivìduo, e para estimulação de proliferação celular em um indivìduo, e, composto
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
PL1828148T3 (pl) * 2004-12-13 2010-08-31 Leo Pharma As Triazol podstawiony związkami aminobenzofenonu
CA2626897A1 (fr) * 2005-11-03 2007-05-18 Joshua Close Inhibiteurs de l'histone desacetylase a motifs d'aryle-pyrazolyle
JP2009535393A (ja) * 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
US7939671B2 (en) 2007-08-21 2011-05-10 Senomyx, Inc. Compounds that inhibit (block) bitter taste in composition and use thereof
AR069650A1 (es) 2007-12-14 2010-02-10 Actelion Pharmaceuticals Ltd Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
DK2432760T3 (da) 2009-05-18 2013-09-08 Actelion Pharmaceuticals Ltd Brokoblede spiro [2.4]-heptanderivater som alx-receptor og/eller fprl2-agonister
US8580831B2 (en) 2009-06-09 2013-11-12 Actelion Pharmaceuticals Ltd. Fluorinated aminotriazole derivatives
CA2760887A1 (fr) 2009-06-12 2010-12-16 Actelion Pharmaceuticals Ltd Derives de l'oxazole et du thiazole en tant qu'agonistes du recepteur alx

Also Published As

Publication number Publication date
CN101903378A (zh) 2010-12-01
CA2706839C (fr) 2015-10-20
CA2706839A1 (fr) 2009-06-25
IL206399A0 (en) 2010-12-30
TW200932216A (en) 2009-08-01
MX2010006241A (es) 2010-06-30
BRPI0821115A8 (pt) 2017-12-26
AU2008337097B2 (en) 2014-03-20
PL2225231T3 (pl) 2012-01-31
RU2010129272A (ru) 2012-01-27
ATE520689T1 (de) 2011-09-15
CN101903378B (zh) 2014-03-12
WO2009077990A1 (fr) 2009-06-25
MY153985A (en) 2015-04-30
EP2225231B1 (fr) 2011-08-17
ZA201005080B (en) 2011-12-28
HK1144158A1 (en) 2011-01-28
KR20100092516A (ko) 2010-08-20
CY1112465T1 (el) 2015-12-09
AR069801A1 (es) 2010-02-17
IL206399A (en) 2016-03-31
BRPI0821115A2 (pt) 2015-06-16
PT2225231E (pt) 2011-10-19
NZ586735A (en) 2012-06-29
RU2492167C2 (ru) 2013-09-10
EP2225231A1 (fr) 2010-09-08
DK2225231T3 (da) 2011-10-17
HRP20110825T1 (hr) 2011-12-31
JP2011506594A (ja) 2011-03-03
AU2008337097A1 (en) 2009-06-25
US20100331378A1 (en) 2010-12-30
TWI434685B (zh) 2014-04-21
SI2225231T1 (sl) 2011-12-30
KR101213007B1 (ko) 2012-12-20
JP4656674B2 (ja) 2011-03-23
US8536209B2 (en) 2013-09-17

Similar Documents

Publication Publication Date Title
MA31949B1 (fr) Dérivés d'aminotriazole comme agonistes d'alx
MA33365B1 (fr) Dérivés de spiro[2.4]heptane pontés utiles en tant qu'agonistes du récepteur de alx et/ou du récepteur fprl2
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA27427A1 (fr) Composes de benzimidazole-1-yl-thiophene utilises en cancerotherapie
MA30207B1 (fr) Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA31766B1 (fr) Composés organiques
MA32655B1 (fr) Composés modulant sélectivement le récepteur cb2
MA28269A1 (fr) Arylpyrazoles substitués servant d'agents parasiticides
MA29378B1 (fr) Composition pharmaceutique comprenant une diphenyluree substituee par un omega-carboxyaryle pour le traitement du cancer
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
MA29685B1 (fr) Composes spiroheterocycliques et leurs utilisations en tant qu'agents therapeutiques
MA29723B1 (fr) Composes
TN2009000324A1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA31952B1 (fr) Pyrrolopyrimidines et pyrrolopyridines
MA27771A1 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines utiles dans le traitement de l'hypertension